Minimally Invasive Surgery Robot NanoScalpel Receives FDA Approval: Surgical Incisions Reduced to 3 Millimeters
Microsure's NanoScalpel ultra-minimally invasive surgery robot system receives FDA approval, with its 3mm diameter surgical arms capable of performing precise operations through incisions half the size of traditional laparoscopic surgery, having completed 500 surgeries across 12 hospitals globally.
Microsure announced on January 13, 2029, that its NanoScalpel ultra-minimally invasive surgery robot system has received FDA approval. The system's surgical arms are only 3 millimeters in diameter, capable of performing equally precise operations through incisions half the size of traditional laparoscopic surgery.
NanoScalpel's core innovation is its piezoelectric-driven micro-joint system. The 7-degree-of-freedom micro-joints give the surgical arm flexibility comparable to human hands, but with 10 times the precision — positioning error no greater than 0.02 millimeters. The system also features force feedback sensors, allowing surgeons to feel resistance when the surgical arm contacts tissue.
Before FDA approval, NanoScalpel completed 500 surgeries across 12 hospitals worldwide, covering general surgery, urology, and gynecology. Post-operative complication rate was 1.2%, lower than traditional laparoscopic surgery's 3.8%. Average patient hospital stay缩短了40%.
Microsure states NanoScalpel is priced at $2.8 million, between traditional laparoscopic equipment and the Da Vinci surgical robot. The company plans to enter 30 countries' medical markets in 2029.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.